Day Two Agenda

8:30 am Check-In & Coffee

9:15 am Chair’s Opening Remarks

Understanding The Effect of Linker Differentiation on Toxicity to to Reduce Off-Target Toxicities

9:30 am Analyzing the Difference in Toxicity Profiles when Linker Stability is Altered in Order to Understand the Root Cause of Toxicity

  • Jutta Deckert Vice President, Research & Development, Iksuda Therapeutics


  • Comparing the benefits of more stable linkers compared to more cleavable linkers
  • Comprehending the mechanism of linker technology to understand premature/late release of the payload
  • Investigating the relationship between linker type and the resulting toxicity 

10:00 am Sharing Data on Pre-Clinical Toxicity Results Upon Use of Cleavable vs Non-Cleavable Linkers


Understanding the relationship of linker stability to tissue-specific toxicities

Optimizing linker stability to improve the toxicity profile of ADCs.

Leveraging knowledge of linkers for the development of novel ADCs

10:30 am Evaluating the Differences in Toxicity of Novel Multilink Linker-Payload Technology


  • Comparing two ADCs with the same antibody and payload to demonstrate the importance of new linker technologies
  • Evaluating the toxicity profile of different linker-payload to improve the therapeutic index
  • Comparing two schedules of treatment in the hope of optimizing the efficacy and the toxicity profile

11:00 am Morning Break & Networking


This session is an opportunity to connect with peers working within the ADC Toxicity world, to have important conversations to overcome shared challenges, and plot paths to see future successes within the field

Improving Prediction of Toxicities through a Reverse Translational Approach

11:30 am Translating from the Clinic to in vitro and Back to Gain an Understanding of Mechanisms of Toxicity

  • Kristin Decker Associate Director Pharmacology and Toxicology, Heidelberg Pharma

12:00 pm Panel – Bench to Bedside & Back – Assessing the Benefits of a Reverse Translational Approach When Minimizing ADC Toxicities


  • Viewing the ways toxicities present themselves clinically to consider what can be done preclinically to mitigate these effects
  • Transferring from human studies to animal studies to obtain a deeper understanding of how different ADCs are distributed across healthy tissues
  • Understanding potential biomarkers for predicting toxicities which present in humans and being able to connect this back to the pre-clinical stage
  • Navigating the concept of translating back and mechanistically blocking the toxicity in vitro

12:45 pm Lunch & Networking

Retooling your ADC to Increase Therapeutic Index

1:45 pm Employing Payloads with Dual MoA to Improve Therapeutic Window of ADC


  • Introducing novel camptothecins with moderate Top1 inhibition, strong anti-tumor potency and improved safety profile
  • Comprehending how dual MoA of novel payloads can contribute to improved therapeutic windows
  • Investigating applications of dual MoA to improve general safety profiles of ADCs

2:15 pm Harnessing and Evaluating the Use of Bicycle Toxin Conjugates in Place of Traditional ADCs to Reduce Toxicities


  • Exploring the use of bicycle peptides as an alternative to antibodies for the delivery of cytotoxic payloads to reduce toxicities
  • Comparison of the toxicity profile of BTCs with standard ADCs
  • Exploring physiochemical properties to reduce off target toxicity

2:45 pm Improving your Therapeutic Index Using Novel Nuclear Delivered ADCs


  • Discover how by understanding target biology, and careful tailoring of ADC design is the key to achieving high therapeutic index
  • Learn the possibilities surrounding the use of AGX101 to increase the therapeutic index up to 10-fold
  • Evaluate the use of nuclear-delivered antibody-drug conjugates, which are now in the clinic, to reduce toxicity

3:15 pm Chair’s Closing Remarks

3:20 pm End of 2nd ADC Toxicity Summit